BBI Life Sciences Corporation announced audited consolidated earnings results for the year ended December 31, 2017. For the year, the company reported revenue of RMB 462,403,000 against RMB 352,026,000 a year ago. Operating profit was RMB 69,313,000 against RMB 64,935,000 a year ago. Profit before income tax was RMB 71,127,000 against RMB 70,644,000 a year ago. Total profit attributable to equity holders of the company was RMB 64,446,000 against RMB 60,183,000 a year ago. Basic and diluted earnings per share for profit attributable to equity holders of the company during the year were RMB 0.118 against RMB 0.111 a year ago. Net cash generated from operating activities was RMB 87,167,000 against RMB 79,278,000 a year ago. During the Reporting Period, the revenue of the Group representing an increase of 31.4% as compared with for the same period of 2016. This was mainly contributed by the steady growth of the Four Business Segments. Property, plant and equipment include buildings, machinery equipment and construction under progress. During the Reporting Period, the expenditure incurred in purchasing property, plant and equipment and of construction in process amounted to RMB 163.02 million.